报价延迟最少15分钟:2025/07/21 06:15 EDT
盘前时段
|
||||
|
0.2838 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2769
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.74/-1.15
|
|
企业价值
8.22M
|
| 资产负债 |
|
每股账面净值
0.13
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:15 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for largepatient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. |
